arGEN-X Concludes EUR 12.5 Million Series A Financing Round
arGEN-X has raised a total of
The Series A round was co-led by Forbion Capital Partners (
arGEN-X will use the proceeds to further develop the Company's proprietary, unencumbered SIMPLE Antibody(TM) engine and to continue to build a proprietary pre-clinical antibody product portfolio. arGEN-X's SIMPLE Antibody(TM) platform yields monoclonal antibodies which combine an unparalleled functional diversity against human disease targets with best in class human germline homology. arGEN-X's SIMPLE Antibodies(TM) are generated in vivo, starting from active immunization, and exhibit ultra high starting affinities and potencies without the need for further engineering.
The arGEN-X platform has the potential to rapidly create exciting product candidates both against novel therapeutic targets and against targets where standard antibody approaches fail to generate an optimal lead diversity.
Tim Van Hauwermeiren, Chief Executive Officer of arGEN-X added: "We are very pleased to have raised this additional funding from two experienced European life science investors. In addition, we are proud to become VIB's first external investment and we view this as a real quality stamp of approval. With substantial funding now in place, arGEN-X is well positioned to execute its ambitious value-creating strategy over the next two years."
Notes for the editor
About arGEN-X - http://www.arGEN-X.com
arGEN-X is a research stage biopharmaceutical company with a broadly applicable, proprietary SIMPLE Antibody(TM) platform. The platform allows arGEN-X to create an unparalleled diversity of in vivo generated antibody leads against a broad range of human disease targets. This superior choice of ultra-high affinity and highly potent leads, having best-in-class human homology, allows for more stringent lead selection criteria, thereby increasing the probability of success later in the drug development path. The Company has validated its monoclonal antibody platform on two human disease targets and has broad patent claims in place covering its technology.
arGEN-X(TM) and SIMPLE Antibody(TM) are deposited trademarks of arGEN-X BV.
SIMPLE stands for Superior Immunodiversity with Minimal Protein Lead Engineering.
About Credit Agricole Private Equity - http://www.ca-privateequity.com
Credit Agricole Private Equity is an AMF-accredited asset-management
subsidiary of Credit Agricole S.A., specialising in direct private-equity
investment in non-listed companies. A multi-specialist player in the
private-equity market, it has a team of 80 professionals operating in a
variety of areas (LBO & Expansion, Venture Capital, Mezzanine, Co-Investment,
Renewable Energy, PPP Infrastructure, etc.), and manages
About VIB - http://www.vib.be
VIB is a non-profit research institute in life sciences. About 1200
scientists conduct strategic basic research on the molecular mechanisms that
are responsible for the functioning of the human body, plants, and
micro-organisms. Through a close partnership with four Flemish universities -
For further information, please contact: Citigate Dewe Rogerson arGEN-X David Dible Tim Van Hauwermeiren, MSc, eMBA Mark Swallow Chief Executive Officer Nina Enegren T: +44-207-282-2949/2948 T: +31-6-122-85-257 E: David.Dible@citigatedr.co.uk E: tim.vh@arGEN-X.com
More by this Source
arGEN-X and de Duve Institute/UCL to Collaborate on Novel Immunomodulation Therapy in Cancer
Nov 04, 2013, 03:00 ET
arGEN-X raises EUR 5 Million from PMV in Extension of EUR 32.5 Million Series B
Nov 04, 2013, 03:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.